据华尔街日报引述知情人士称,强生正与生物制药公司Protagonist Therapeutics商谈收购事宜。强生目前已与Protagonist合作开发免疫疾病治疗药物。Protagonist同时与武田制药(Takeda Pharmaceutical)合作研发治疗罕见血癌的药物Rusfertide。若交易达成,将有助强生在其重磅免疫治疗药物Stelara面临低价仿制药竞争之际巩固产品线。
据华尔街日报引述知情人士称,强生正与生物制药公司Protagonist Therapeutics商谈收购事宜。强生目前已与Protagonist合作开发免疫疾病治疗药物。Protagonist同时与武田制药(Takeda Pharmaceutical)合作研发治疗罕见血癌的药物Rusfertide。若交易达成,将有助强生在其重磅免疫治疗药物Stelara面临低价仿制药竞争之际巩固产品线。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.